ArriVent BioPharma Inc Dossier
Qualitative Analysis
Business overview
ArriVent BioPharma, Inc. (Nasdaq: AVBP) is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Founded in April 2021, the company focuses on globalizing biopharma innovations sourced from international markets. Its lead product candidate is firmonertinib, a tyrosine kinase inhibitor (TKI) being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC). Beyond firmonertinib, ArriVent is building a pipeline of next-generation antibody-drug conjugates (ADCs), including CDH17-targeted ARR-217 and dual-target MUC16/NaPi2b tetravalent ARR-002.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead oral EGFR inhibitor, firmonertinib, through two global pivotal Phase 3 trials: FURVENT (first-line EGFR exon 20 insertion mutant NSCLC) and ALPACCA (first-line EGFR PACC mutant NSCLC).
Expected impact: Establish firmonertinib as a differentiated, potentially best-in-class treatment option for underserved uncommon EGFR mutations, enabling regulatory approvals outside Greater China.
Building a diversified oncology pipeline of next-generation ADCs, led by ARR-217 (targeting CDH17 for GI cancers) and ARR-002 (a dual-targeting MUC16/NaPi2b tetravalent ADC for ovarian and endometrial cancers).
Expected impact: Mitigate clinical concentration risk by establishing a robust, multi-asset oncology portfolio beyond the lead tyrosine kinase inhibitor.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Licensed the exclusive rights to develop, manufacture, and commercialize lead candidate firmonertinib worldwide, excluding Greater China.
Terms: Subject to development, regulatory, and sales milestones, alongside tiered royalties on net sales outside Greater China.
Acquired exclusive global rights (excluding Greater China) to develop and commercialize ARR-217 (MRG007), a CDH17-targeted ADC for gastrointestinal cancers.
Terms: Upfront and near-term milestone payments totaling $47 million in cash, with eligibility for up to $1.16 billion in development, regulatory, and sales milestones, plus tiered royalties.
Collaborating on the discovery and preclinical validation of ARR-002, a novel dual-targeting MUC16/NaPi2b tetravalent ADC, with ArriVent leading clinical development and commercialization.
Terms: ArriVent is responsible for clinical development and commercialization costs, with Aarvik eligible for milestone payments and royalties.
Leveraging Alphamab's proprietary linker-payload platform and glycan-conjugation technology to discover, develop, and commercialize novel ADCs globally (excluding Greater China).
Terms: Alphamab is eligible for upfront, milestone, and royalty payments, retaining development and commercialization rights in Greater China.